• Search
  • Advanced Search

Search

  • HOME
  • Search
Review
2107
Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease
Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan
Clin Mol Hepatol. 2025;31(Suppl):S94-S111.   Published online November 28, 2024
View: 4425   Download: 337  Web of Science: 5  Crossref: 6
Special Issue
2190
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025
Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2025;31(Suppl):S1-S31.   Published online February 19, 2025
View: 1414   Download: 171  Web of Science: 2  Crossref: 3
Reply to Correspondence
Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(2):e218-e220.   Published online February 3, 2025
View: 769   Download: 27
Correspondence
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol. 2025;31(2):e210-e211.   Published online January 6, 2025
View: 1097   Download: 25
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol. 2025;31(2):e208-e209.   Published online January 6, 2025
View: 1105   Download: 23
Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”
Ji Won Han, Dae Won Jun
Clin Mol Hepatol. 2025;31(2):e152-e154.   Published online December 30, 2024
View: 1018   Download: 31
Letter to the Editor
Prevalence of steatotic liver disease and associated fibrosis in the general population: An epidemiological survey: Letter to the editor on “Epidemiology of metabolic dysfunction-associated steatotic liver disease”
Lin Guan, Xinhe Zhang, Shanghao Liu, Xiaolong Qi, Yiling Li
Clin Mol Hepatol. 2025;31(2):e145-e148.   Published online October 29, 2024
View: 1331   Download: 81
Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Hai Xu, Yong Zhou, Huikun Wu
Clin Mol Hepatol. 2025;31(2):e125-e127.   Published online December 17, 2024
View: 1017   Download: 33  Crossref: 1
Editorial
A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”
Jing Zeng, Jian-Gao Fan
Clin Mol Hepatol. 2025;31(2):610-614.   Published online December 17, 2024
View: 1010   Download: 42  Web of Science: 1  Crossref: 2
2090
Stabilizing hepatic fatty acid oxidation: Editorial on “USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination”
Myeung Gi Choi, Na Young Lee, Ja Hyun Koo
Clin Mol Hepatol. 2025;31(2):592-595.   Published online November 6, 2024
View: 1455   Download: 80
Correspondence
2032
PNPLA3 is one of the bridges between TM6SF2 E167K variant and MASLD: Correspondence to editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Baokai Sun, Likun Zhuang
Clin Mol Hepatol. 2025;31(1):e67-e69.   Published online September 10, 2024
View: 1139   Download: 81
Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”
Young Eun Chon, Jung Hwan Yu, Seung Up Kim
Clin Mol Hepatol. 2025;31(1):e61-e63.   Published online October 15, 2024
View: 1094   Download: 30
Letter to the Editor
Sex-specific associations of metabolic dysfunction-associated steatotic liver disease with cardiovascular outcomes
Meng-Yuan Miao, Jie-Qiong Lyu, Wei Jiang, Zhong-Yue Liu, Guo-Chong Chen
Clin Mol Hepatol. 2025;31(1):e35-e38.   Published online September 20, 2024
View: 1270   Download: 73  Web of Science: 1  Crossref: 1
Editorial
TM6SF2 and PNPLA3: A potential dynamic duo?: Editorial on “TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD”
Andrea Caddeo, Rosellina M. Mancina
Clin Mol Hepatol. 2025;31(1):293-296.   Published online August 27, 2024
View: 1440   Download: 109  Crossref: 3
Essential tools for assessing advanced fibrosis in metabolic dysfunction-associated steatotic liver disease: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
Won Sohn
Clin Mol Hepatol. 2025;31(1):277-280.   Published online October 11, 2024
View: 1567   Download: 44  Crossref: 1
Towards unification of liver stiffness measurement cutoffs: Editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”
Yangyue Zhang, Vincent Wai-Sun Wong
Clin Mol Hepatol. 2025;31(1):264-267.   Published online September 20, 2024
View: 1851   Download: 52  Crossref: 1
Original Article
2101
Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis
Nicholas A. Rouillard, Scott D. Barnett, Xinrong Zhang, Leslie Kam, Richie Manikat, Ramsey Cheung, Mindie H. Nguyen
Clin Mol Hepatol. 2025;31(1):227-239.   Published online November 14, 2024
View: 1978   Download: 147  Web of Science: 4  Crossref: 6
2051
USP29 alleviates the progression of MASLD by stabilizing ACSL5 through K48 deubiquitination
Sha Hu, Zhouxiang Wang, Kun Zhu, Hongjie Shi, Fang Qin, Tuo Zhang, Song tian, Yanxiao Ji, Jianqing Zhang, Juanjuan Qin, Zhigang She, Xiaojing Zhang, Peng Zhang, Hongliang Li
Clin Mol Hepatol. 2025;31(1):147-165.   Published online October 2, 2024
View: 4036   Download: 578  Web of Science: 4  Crossref: 3
Review
2073
Bioactive metabolites: A clue to the link between MASLD and CKD?
Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun
Clin Mol Hepatol. 2025;31(1):56-73.   Published online October 21, 2024
View: 2673   Download: 197  Crossref: 1
2048
Roles of X-box binding protein 1 in liver pathogenesis
Jihoon Tak, Yun Seok Kim, Sang Geon Kim
Clin Mol Hepatol. 2025;31(1):1-31.   Published online October 2, 2024
View: 2771   Download: 179  Web of Science: 1  Crossref: 1
Special Topic
A new Korean nomenclature for steatotic liver disease
Nonalcoholic Fatty Liver Disease (NAFLD) Nomenclature Revision Consensus Task Force on behalf of the Korean Association for the Study of the Liver (KASL)
Clin Mol Hepatol. 2024;30(Suppl):S214-S216.   Published online July 1, 2024
View: 1954   Download: 95  Crossref: 2
Reply to Correspondence
Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clin Mol Hepatol. 2024;30(4):1039-1041.   Published online September 24, 2024
View: 1317   Download: 31
Correspondence
1962
The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li
Clin Mol Hepatol. 2024;30(4):1019-1022.   Published online July 8, 2024
View: 1914   Download: 62
Letter to the Editor
Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality
Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Clin Mol Hepatol. 2024;30(4):982-986.   Published online August 27, 2024
View: 1900   Download: 67  Web of Science: 1  Crossref: 1
Original Article
1985
TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD
Baokai Sun, Xiaoqian Ding, Jie Tan, Jie Zhang, Xueru Chu, Shuimi Zhang, Shousheng Liu, Zhenzhen Zhao, Shiying Xuan, Yongning Xin, Likun Zhuang
Clin Mol Hepatol. 2024;30(4):863-882.   Published online July 26, 2024
View: 3139   Download: 280  Web of Science: 6  Crossref: 6
Editorial
1944
Ursolic acid: A promising therapeutic agent for metabolic dysfunction-associated steatotic liver disease via inhibition of SPP1-induced Th17 cell differentiation: Editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”
So Jung Kim, Jeongeun Hyun
Clin Mol Hepatol. 2024;30(4):709-713.   Published online June 11, 2024
View: 2384   Download: 86  Web of Science: 2  Crossref: 3
1976
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”
Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan
Clin Mol Hepatol. 2024;30(4):649-652.   Published online July 23, 2024
View: 2410   Download: 102  Web of Science: 3  Crossref: 2
Snapshot
1874
Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations
Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen
Clin Mol Hepatol. 2024;30(3):582-584.   Published online December 29, 2023
View: 10045   Download: 106
Letter to the Editor
1902
Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia
Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi
Clin Mol Hepatol. 2024;30(3):577-579.   Published online March 6, 2024
View: 3238   Download: 176  Web of Science: 11  Crossref: 10
Original Article
1917
Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease
Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li
Clin Mol Hepatol. 2024;30(3):449-467.   Published online April 16, 2024
View: 6312   Download: 437  Web of Science: 12  Crossref: 12
1 | 2 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: cmh_journal@ijpnc.com
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 174
TOTAL : 2771674
Close layer